Business
Chimeric IPO: What ASX stockspert Bhavdip143 likes so much about the $35m CAR T play – Stockhead
Institutional investors have queued up to buy stock in Chimeric’s IPO ‘CAR T cell therapy is one of the hottest areas in biotech’ ASX stocks commentator Bhavdip143…
Link copied toclipboard
- Institutional investors have queued up to buy stock in Chimeric’s IPO
- ‘CAR T cell therapy is one of the hottest areas in biotech’ ASX stocks commentator Bhavdip143
- IPO for $35m will fully fund stage one and two clinical trials for CAR T cell treatment
CAR T cell treatment company Chimeric Therapeutics (ASX:CHM) is understood to have easily achieved its IPO fundraising target of $35m ahead of its ASX listing timed for Monday.
Institutional investors have expressed strong interest…
Continue Reading
-
Noosa News6 hours agoAttempted murder charges, Maroochydore – Sunshine Coast
-
Business14 hours agoHow much passive income could I earn with 1,000 BHP shares?
-
Noosa News10 hours agoWoman fighting for life and others left seriously injured in Sunshine Coast hit-and-run
-
General10 hours agoMelbourne’s West Gate Tunnel opens to divert trucks through city’s western suburbs